← All trials
NCT02913664
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Sep 1, 2021
- Completion date
- Sep 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 640
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- The University of Texas, DallasLead sponsor
- Texas Health ResourcesOverall official - principal investigator
- University of VermontOverall official - principal investigator
- Texas Health ResourcesCollaborator
- Michigan State UniversityCollaborator
- University of VermontCollaborator
- Washington University in St. LouisOverall official - principal investigator
- Washington University in St. LouisCollaborator
- University of KansasCollaborator
- University of KansasOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
- The University of Texas, DallasReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.